LAVAL, Québec et CAMBRIDGE, Angleterre, 18 septembre 2023 /PRNewswire/ — Liminal BioSciences Inc. (Nasdaq: LMNL) (« Liminal BioSciences » ou la « Société »), a le plaisir d’annoncer que ses actionnaires ont approuvé le plan d’arrangement annoncé précédemment en vertu de l’article 192 de…
This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.